➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Harvard Business School
Dow
McKesson
Johnson and Johnson

Last Updated: May 10, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TEDUGLUTIDE RECOMBINANT

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Teduglutide Recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00081458 Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Completed Shire Phase 3 2004-04-01 The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of teduglutide compared with placebo in subjects with parenteral nutrition (PN)-dependent short bowel syndrome (SBS).
NCT00172185 Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458) Completed Shire Phase 3 2005-01-01 The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.
NCT00308438 Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008 Completed Shire Phase 2 2004-03-01 The purpose of the study is to determine whether an investigational compound, ALX-0600, is safe and effective in treating Crohn's Disease.
NCT00798967 Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects Completed Nycomed Phase 3 2008-11-01 Teduglutide is an investigative medicine being evaluated as a possible treatment for people with parenteral nutrition (PN) dependent Short Bowel Syndrome (SBS). Teduglutide is similar to a protein the body makes. When people have SBS, their bodies do not make enough of the protein and they have trouble getting nutrients and fluids from the food they eat and drink. This study was designed to provide evidence of efficacy, safety, and tolerability of teduglutide 0.05 mg/kg daily in SBS subjects.
NCT00798967 Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects Completed Shire Phase 3 2008-11-01 Teduglutide is an investigative medicine being evaluated as a possible treatment for people with parenteral nutrition (PN) dependent Short Bowel Syndrome (SBS). Teduglutide is similar to a protein the body makes. When people have SBS, their bodies do not make enough of the protein and they have trouble getting nutrients and fluids from the food they eat and drink. This study was designed to provide evidence of efficacy, safety, and tolerability of teduglutide 0.05 mg/kg daily in SBS subjects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Teduglutide Recombinant

Condition Name

Condition Name for Teduglutide Recombinant
Intervention Trials
Short Bowel Syndrome 17
Hyperlipidemias 4
Healthy Volunteers 2
Crohn Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Teduglutide Recombinant
Intervention Trials
Syndrome 17
Short Bowel Syndrome 17
Hyperlipoproteinemias 4
Hyperlipidemias 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Teduglutide Recombinant

Trials by Country

Trials by Country for Teduglutide Recombinant
Location Trials
United States 88
Canada 19
United Kingdom 12
Germany 10
Japan 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Teduglutide Recombinant
Location Trials
New York 8
Ohio 7
Pennsylvania 6
Georgia 5
California 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Teduglutide Recombinant

Clinical Trial Phase

Clinical Trial Phase for Teduglutide Recombinant
Clinical Trial Phase Trials
Phase 4 3
Phase 3 16
Phase 2/Phase 3 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Teduglutide Recombinant
Clinical Trial Phase Trials
Completed 15
Not yet recruiting 10
Recruiting 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Teduglutide Recombinant

Sponsor Name

Sponsor Name for Teduglutide Recombinant
Sponsor Trials
Shire 20
University Health Network, Toronto 4
Nycomed 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Teduglutide Recombinant
Sponsor Trials
Industry 26
Other 17
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
AstraZeneca
McKesson
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.